Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

This 8-week, multi-center, open-label study assessed the safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Patients (n=32) with mean sitting systolic blood pressure (msSBP) ⩾140 mm Hg (after a 2–5-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Sadayoshi, Satoh, Minoru, Tamaki, Yuko, Gotou, Hiromi, Charney, Alan, Okino, Naoko, Akahori, Mizuki, Zhang, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396400/
https://www.ncbi.nlm.nih.gov/pubmed/25693859
http://dx.doi.org/10.1038/hr.2015.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396400/
https://www.ncbi.nlm.nih.gov/pubmed/25693859
http://dx.doi.org/10.1038/hr.2015.1

Ejemplares similares